Alcon launches PanOptix trifocal intraocular lens for cataract patients in US

Alcon has commercially launched AcrySof IQ PanOptix trifocal intraocular lens (IOL) in the US after its approval by the US Food and Drug Administration (FDA).

PanOptix is said to be the first trifocal lens to be approved by the FDA for patients undergoing cataract surgery in the US. The FDA approval was based on data from the pivotal trial study carried out at 12 investigational locations across the US in which the trifocal intraocular lens is said to have shown exceptional, uninterrupted vision.

According to Alcon, Pan Optix has been demonstrated clinically to provide a better combination of near, intermediate and far vision, while substantially lowering the need for wearing glasses post-surgery.

The multifocal intraocular lens has been designed to focus images clearly onto the back of the retina for clear vision after the removal of the cataract.

Alcon PanOptix trifocal intraocular lens

Product shot of Alcon PanOptix trifocal intraocular lens. Photo courtesy of Business Wire, Inc.

The PanOptix trifocal intraocular lens has been designed by Alcon to suit the present day’s active lifestyle of viewing computer screens and mobile devices, and also for high-quality distance vision in a variety of lighting conditions.

Kerry Solomon from Carolina Eyecare Physicians and PanOptix clinical trial investigator said: “We know patients undergoing cataract surgery today want a replacement lens that delivers the vision they need to live full, active lives without always being dependent on glasses. PanOptix is an excellent lens option to address these needs and is clinically proven to deliver an outstanding range of vision.”

The trifocal intraocular lens from Alcon uses Enlighten optical technology, which is said to be an advanced design for boosting intermediate vision without impacting near and distance vision.

PanOptix, which was developed based on the AcrySof IQ IOL platform, has been launched in toric and also spherical designs.

David J. Endicott – CEO of Alcon said: “We are proud to bring this new class of IOLs to the largest eye care market in the world. We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons.

“Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”

Share This